The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers
about
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldAllelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft modelMolecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.ICON: Eosinophil DisordersPreclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisA real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview.Associations of Physical and Psychologic Symptom Burden in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
P2860
Q27003331-DA8F7304-AB19-4D8E-AEF2-E1A5E80ED08AQ34562099-2F52D9E0-1C94-4DAE-8BAA-9B1D28E0F3BCQ34906157-BC340B8E-A60C-4C02-B6CC-F53AF1790173Q36153557-7C6620B1-01BF-42F6-A986-A194D82DE09EQ36834826-5C0D4DD9-22E7-4008-82E3-65769BE2BA37Q37327244-BE76F2BB-8314-435F-8AA3-1044BBAD228EQ37705695-EA3295CE-411E-4CF0-8FEF-4A7BA7319DC5Q41525402-400AE50F-A7B4-40D9-9334-BCCD3036DF04Q41627599-3CE7532F-7F1E-4563-A677-14E9FBD2A8A3Q43122604-3213565D-15FF-4105-BADD-ED06F23397A8Q50532563-0760EFCF-056D-4236-81D3-FCD66C0C880FQ55026206-85186B05-CBFE-4A39-83EF-9EC2AC57C9E1
P2860
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@ast
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@en
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@nl
type
label
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@ast
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@en
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@nl
prefLabel
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@ast
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@en
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@nl
P2860
P50
P1433
P1476
The diagnosis of BCR/ABL-negat ...... enetics, and molecular markers
@en
P2093
Wolfgang Kern
P2860
P356
10.1007/S00277-007-0403-6
P407
P577
2008-01-01T00:00:00Z